Deterministic preview of the disease pipeline landscape — Phase 2/3 trial counts...

{ "method": "GET", "queryParams": { "condition": "Disease area — e.g. \"Parkinson Disease\" | \"Breast Cancer\" | \"NASH\" | \"Heart Failure\" | \"Schizophrenia\"" }, "type": "http" }

{ "errors": { "400": { "description": "Invalid or missing parameter(s). Returned before the payment gate on paid requests, so a malformed call is never charged. JSON body: { error: <what is wrong and how to fix it> } plus usage hints.", "example": { "error": "invalid request" } }, "402": { "description": "Payment required — x402 v2 challenge; the accepts array lists scheme, network, and amount. Retry the same request with a PAYMENT-SIGNATURE (v2) or X-PAYMENT (v1) header. Verification is free." }, "500": { "description": "Unexpected server error. If a payment settled without a usable result, contact info@theaslangroupllc.com with the settlement tx hash for a re-run or credit.", "example": { "error": "upstream_failed" } } }, "example": { "deterministic": true, "pipeline_overview": { "completed_total": 210, "phase2_count": 48, "phase3_count": 19, "total_active": 67 }, "query_summary": { "as_of": "2026-07-25", "condition": "NASH (Nonalcoholic Steatohepatitis)" }, "sample_phase3_trials": [ { "nctId": "NCT04858633", "sponsor": "Novo Nordisk A/S", "status": "ACTIVE_NOT_RECRUITING", "title": "Semaglutide in NASH" } ], "status_breakdown": { "ACTIVE_NOT_RECRUITING": 22, "COMPLETED": 14, "RECRUITING": 31 }, "top_countries": [ { "country": "United States", "trial_count": 40 } ], "top_sponsors": [ { "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "trial_count": 6 } ], "upsell": { "adds": "Approved drugs, mechanism-of-action landscape (crowded/emerging/gaps), PDUFA calendar, M&A deal activity, investment thesis, 0-100 opportunity score.", "full_product": "/api/clinical/disease-landscape", "price_usd": 0.35 } }, "type": "json" }